Pneumonia diagnostic technology gains US patent:
This article was originally published in Clinica
Executive Summary
US firm Genomics Collaborative has been awarded a US patent covering a technology that could lead to the development of a diagnostic screening tool for determining predisposition to pneumonia and sepsis. "By identifying factors that predispose patients to pneumonia and even an increased risk of death, we can select and develop aggressive treatment regimens, says Dr Kevin Krenitsky, the firm's medical director. The patent is entitled "Method of diagnosing and treating community acquired pneumonia (CAP) associated with the A-allele of TNFalpha-238 polymorphism."